sisomicin
ApprovedSmall molecule
Merck & Co.sisomicin is one of 10 small molecule programs targeting Pyoderma. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Pyoderma
#DrugCompanyPhaseTrials
1Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Humira
CCelltrion
Phase 3
Velsipity
PfizerPhase 2
Taltz
Eli LillyPhase 2
Cosentyx
NovartisPhase 2
Ilaris
NovartisPhase 2
Spevigo
Boehringer IngelheimPhase 2
sisomicin
Merck & Co.Approved
Hydroxymethylquinoxalindioxyde
VValenta Pharm JSC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sisomicin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company